The agreement comprises up to four Lilly proprietary drug compounds.*

“We are pleased to enter into this collaboration with Lilly to bring innovative long-acting treatment options to people living with obesity, diabetes, and other serious chronic diseases,” says Fredrik Tiberg, President & CEO, CSO of Camurus. “Through the collaboration with Lilly, a global leader in the metabolic disease area, we leverage our FluidCrystal technology in rapidly expanding indication areas impacting hundreds of millions of people, while maintaining our own commercial focus on CNS and rare diseases.”

Up to USD 290 million in upfront, development, and regulatory milestone payments

In return for granting Lilly the license to use the FluidCrystal technology for the selected incretin drug compounds for cardiometabolic health, Camurus is eligible to receive up to USD 290 million in upfront, development, and regulatory milestone payments as well as USD 580 million in sales-based milestone payments and tiered mid-single digit royalties on global net product sales.

*Selected from dual GIP and GLP-1 receptor agonists, triple GIP, glucagon and GLP-1 receptor agonists, and an option to include amylin receptor agonists.